Viyash Scientific · tone and specificity signals across the available quarters.
Language signals
This is the first time we are discussing quarterly results of the merged entity Sequent and V together as one company. More than the numbers, it's a reflection of what we have built over the last few quarters—one integrated platform, one operating cadence and one team working towards the same outcomes.
Q3 FY26 reflects steady progress on growth and steep change in profitability and balance sheet strength. Revenue from operations for Q3 FY26 was 858 crores grown up by 11% year-on-year. Adjusted EBITDA was 185 crores grown by 64% year-over-year with an EBITDA margin of 21% and expansion of 390 basis points.
Our core strengths are anchored in R&D, manufacturing and intellectual property, and that is what allows us to move the portfolio up to the value curve. We are a R&D first organization to launch new products that is genuinely scaled and capable.
Companion animal is one of the most attractive long-term opportunity for us supported by increasing pet ownership and also the genericization runway in animal health. If you see, genericization has happened only 15% whereas comparatively little more on farm animals and in human health 85-90%. That's where we see the opportunity for next couple of years.